Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...
Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...
In the AUGMENT-101 trial, 21 percent of patients achieved complete remission plus complete remission with partial hematological recovery on the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback